- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cheryl Larson on How Employers Can Get Biosimilars Added to Their Health Plan
We sat down with Cheryl Larson, president and CEO of Midwest Business Group on Health (MBGH), an employer coalition based in Chicago, Illinois, to discuss the current obstacles employers face in getting biosimilars added to their formularies and what steps they can take to get around them.
With the cost of biopharmaceuticals on the rise, employers are looking to biosimilars as a way to cut costs for themselves and their employees now more than ever. However, because the decision-making power for formularies rests mostly with payers and pharmacy benefit managers (PBMs), employers have seen few biosimilars added to their lists despite there being an increase in the number of biosimilar products that are on the US market.
We sat down with Cheryl Larson, president and CEO of Midwest Business Group on Health (MBGH), an employer coalition based in Chicago, Illinois, to discuss the current obstacles employers face in getting biosimilars added to their formularies and what steps they can take to get around them.
To learn more about MBGH's call to action for employers, click here.
To learn more about MBGH's biosimilars report, click here.
To learn more about Midwest Business Group on Health, click here.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
